Lycia

Lycia Therapeutics plans $317.5M IPO; Merck halts sac-TMT trial; Hexagon Bio raises $62M; Mineralys Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the…

ENDPOINTS · 2026-10-23

Plus news about Hexagon Bio, Mineralys Therapeutics and Arbor Biotechnologies. Lycia prices $317.5 million IPO: Lycia Therapeutics, a company founded by Nobel Prize winner Carolyn Bertozzi, is pricing its initial public ...

Source: Endpoints News